Advertisement
Advertisement
Gemini Therapeutics, Inc. (GMTX)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
As of 12:00PM EDT. Market open.
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 1.6000 |
| Open | 1.6600 |
| Bid | 1.6300 x 900 |
| Ask | 1.6800 x 2900 |
| Day's Range | 1.5800 - 1.6600 |
| 52 Week Range | 1.1600 - 6.6100 |
| Volume | |
| Avg. Volume | 233,629 |
| Market Cap | 71.352M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8500 |
| Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.88 |
- Simply Wall St.
Insider Buying: Braden Leonard Just Spent US$75k On Gemini Therapeutics, Inc. (NASDAQ:GMTX) Shares
Even if it's not a huge purchase, we think it was good to see that Braden Leonard, a Gemini Therapeutics, Inc...
- Business Wire
Gemini Therapeutics Reports 2021 Financial Results
Remote-First-Company/Mass., March 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.
- Business Wire
Gemini Therapeutics Provides Corporate Update
Remote-First-Company/Mass., February 28, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
